Tolerance Bio Adds Tanabe’s Anti-IL-33 Antibody in Deal Worth Up to $560M
- Tolerance Bio takes global development rights and ex-Japan commercial rights to Tanabe Pharma's clinical-stage anti-IL-33 antibody MT-2990, renamed TLB-33, in a deal with milestones that could reach $560 million.
- The antibody has been tested in more than 150 patients across five trials; Tolerance plans a Phase 2 study on preserving thymic function and immune resilience.
💡 Points
Second thymus-themed in-license in a month: Tolerance is assembling a pipeline around one biological thesis using de-risked clinical assets rather than its own discovery. That is capital-efficient, but it means the company's value rests on the thymus hypothesis being right, not on any single molecule. Pharma sellers get a clean exit for a deprioritized antibody, the usual pattern for mid-stage assets.
Tolerance continues thymus-focused deals with $560M pact for Tanabe's… ↗